Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should minimal residual disease guide therapy in AML?

Best practice & research. Clinical haematology - 1 Jan 2000

Paietta Elisabeth

Abstract excerpt

The prognostic power of minimal residual disease after therapy for acute leukemias is not in question. It is only logical that the finding of leukemic blast cells after therapy predicts for impending relapse or at least the need for additional treatment. Which level of what is called minimal residual disease (MRD) is clinically relevant, however, depends on the efficacy of the initial treatment as well as the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Remission Induction
Share to Biological Assay
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Positron-Emission Tomography

Share to Recurrence

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 26590765
DOI: 10.1016/j.beha.2015.10.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should minimal residual disease guide therapy in AML?PMID 26590765Read ↗

Minimal residual disease in acute myeloid leukemia: coming of age.Semantic proximity Read ↗

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaSemantic proximity Read ↗

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.Semantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Semantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Detection of minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantationSemantic proximity Read ↗

Detection and management of minimal residual disease in acute lymphoblastic leukemiaSemantic proximity Read ↗

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Minimal residual disease and stem cell transplantation outcomes.Semantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.